SG10201407935YA - Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle) - Google Patents

Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)

Info

Publication number
SG10201407935YA
SG10201407935YA SG10201407935YA SG10201407935YA SG10201407935YA SG 10201407935Y A SG10201407935Y A SG 10201407935YA SG 10201407935Y A SG10201407935Y A SG 10201407935YA SG 10201407935Y A SG10201407935Y A SG 10201407935YA SG 10201407935Y A SG10201407935Y A SG 10201407935YA
Authority
SG
Singapore
Prior art keywords
sle
antibodies
treatment
lupus erythematosus
systemic lupus
Prior art date
Application number
SG10201407935YA
Other languages
English (en)
Inventor
Frank Osterroth
Christoph Uherek
Christoph Bruecher
Peter Röttgen
Benjamin Daelken
André Engling
Chantal Zuber
Niklas Czeloth
Original Assignee
Biotest Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0920933A external-priority patent/GB0920933D0/en
Priority claimed from GB0920940A external-priority patent/GB0920940D0/en
Priority claimed from GB0920942A external-priority patent/GB0920942D0/en
Application filed by Biotest Ag filed Critical Biotest Ag
Publication of SG10201407935YA publication Critical patent/SG10201407935YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201407935YA 2009-11-30 2010-11-30 Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle) SG10201407935YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0920933A GB0920933D0 (en) 2009-11-30 2009-11-30 Agent for treating disease
GB0920940A GB0920940D0 (en) 2009-11-30 2009-11-30 Agent for treating disease
GB0920942A GB0920942D0 (en) 2009-11-30 2009-11-30 Agent for treating disease

Publications (1)

Publication Number Publication Date
SG10201407935YA true SG10201407935YA (en) 2015-01-29

Family

ID=43798505

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201407935YA SG10201407935YA (en) 2009-11-30 2010-11-30 Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)
SG10201407936XA SG10201407936XA (en) 2009-11-30 2010-11-30 Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201407936XA SG10201407936XA (en) 2009-11-30 2010-11-30 Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)

Country Status (17)

Country Link
US (4) US8852871B2 (ko)
EP (2) EP2470209B1 (ko)
JP (2) JP2013511994A (ko)
KR (2) KR101802260B1 (ko)
CN (2) CN102811736B (ko)
AU (2) AU2010323036B2 (ko)
BR (2) BR112012012912A2 (ko)
CA (2) CA2782007C (ko)
CO (1) CO6561779A2 (ko)
CR (2) CR20120358A (ko)
IL (2) IL219954A (ko)
MX (2) MX343228B (ko)
NZ (2) NZ600894A (ko)
RU (2) RU2587622C2 (ko)
SG (2) SG10201407935YA (ko)
WO (2) WO2011064399A1 (ko)
ZA (1) ZA201204843B (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102811736B (zh) 2009-11-30 2016-01-20 生物测试股份公司 治疗系统性红斑狼疮(sle)的人源化抗il-10抗体
US9943568B2 (en) 2013-04-18 2018-04-17 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating cancer
US20160068583A1 (en) * 2013-04-24 2016-03-10 Armo Biosciences, Inc. Interleukin-10 Compositions and Uses Thereof
ES2688206T3 (es) 2013-06-17 2018-10-31 Armo Biosciences, Inc. Procedimiento de evaluación de la identidad y la estabilidad de proteínas
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
WO2015070060A1 (en) 2013-11-11 2015-05-14 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CA2938152A1 (en) * 2014-02-10 2015-08-13 Merck Sharp & Dohme Corp. Antibodies that bind to human tau and assay for quantifying human tau using the antibodies
US10725030B2 (en) 2014-11-28 2020-07-28 Ge Healthcare Bio-Sciences Ab Method for determining analyte-ligand binding on a sensor surface
RU2017122172A (ru) * 2014-12-15 2019-01-17 МорфоСис АГ Антитела к IL-17C
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
EP3302547A1 (en) 2015-05-28 2018-04-11 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
EP3341012A4 (en) 2015-08-25 2019-03-20 Armo Biosciences, Inc. METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
US10144768B2 (en) 2015-12-04 2018-12-04 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
WO2019072566A1 (en) 2017-10-10 2019-04-18 Biotest Ag COMBINATION OF ANTI-IL10 AND ANTI-PD1 ANTIBODIES FOR THE TREATMENT OF CANCER
AR114112A1 (es) 2018-02-15 2020-07-22 Seattle Genetics Inc Anticuerpos de glipicano 3 y conjugados de los mismos
US11324750B2 (en) 2020-04-09 2022-05-10 Children's Hospital Medical Center Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
EP3892280A3 (en) 2020-04-09 2022-01-12 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
WO2021206766A1 (en) 2020-04-09 2021-10-14 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
AU2021383537A1 (en) 2020-11-18 2023-06-29 Astrazeneca Ab Steroid sparing
IL305969A (en) * 2021-03-23 2023-11-01 Organogenesis Inc Kits and composition methods for characterizing the anti-inflammatory response of a product

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0567586T3 (da) * 1991-01-16 1995-12-04 Schering Corp Anvendelse af interleukin-10 ved adoptiv immunterapi af cancer
CA2103059C (en) * 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
DK0600970T3 (da) 1991-08-06 2000-05-29 Schering Corp Anvendelse af interleukin-10-analoger eller -antagonister til behandling af endotoksin- eller superantigeninduceret tokscit
US5833976A (en) 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
DE19529026C2 (de) 1995-07-28 1997-06-19 Robert Sabat Monoklonale Antikörper gegen humanes Interleukin-10
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
PE20090046A1 (es) * 2003-11-10 2009-01-26 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
NO2195023T3 (ko) 2007-08-29 2018-08-04
CN102811736B (zh) * 2009-11-30 2016-01-20 生物测试股份公司 治疗系统性红斑狼疮(sle)的人源化抗il-10抗体

Also Published As

Publication number Publication date
KR20120103664A (ko) 2012-09-19
RU2587622C2 (ru) 2016-06-20
US20150218270A1 (en) 2015-08-06
US9605066B2 (en) 2017-03-28
NZ600894A (en) 2014-09-26
AU2010323037A1 (en) 2012-07-19
ZA201204843B (en) 2020-02-26
CR20120358A (es) 2013-01-23
CA2782007A1 (en) 2011-06-03
CN102711829A (zh) 2012-10-03
US20150064179A1 (en) 2015-03-05
US8852871B2 (en) 2014-10-07
EP2470208A1 (en) 2012-07-04
JP2013511994A (ja) 2013-04-11
AU2010323036B2 (en) 2015-01-29
CN102711829B (zh) 2016-03-16
MX2012006197A (es) 2012-06-19
SG10201407936XA (en) 2015-01-29
US8956607B2 (en) 2015-02-17
BR112012012912A2 (pt) 2016-10-25
IL219955A0 (en) 2012-07-31
AU2010323036A1 (en) 2012-07-19
CO6561779A2 (es) 2012-11-15
CA2782004A1 (en) 2011-06-03
RU2581812C2 (ru) 2016-04-20
WO2011064399A1 (en) 2011-06-03
RU2012127381A (ru) 2014-01-10
RU2012127380A (ru) 2014-01-10
CA2782007C (en) 2018-07-24
AU2010323037B2 (en) 2015-01-29
US20120321618A1 (en) 2012-12-20
BR112012012917A2 (pt) 2016-10-25
KR101802261B1 (ko) 2017-11-28
EP2470209A1 (en) 2012-07-04
CN102811736B (zh) 2016-01-20
US9540436B2 (en) 2017-01-10
WO2011064398A1 (en) 2011-06-03
IL219954A0 (en) 2012-07-31
MX2012006198A (es) 2012-06-19
US20120321617A1 (en) 2012-12-20
JP6005519B2 (ja) 2016-10-12
CR20120359A (es) 2013-01-25
IL219955A (en) 2016-08-31
EP2470209B1 (en) 2020-01-01
IL219954A (en) 2016-10-31
KR101802260B1 (ko) 2017-11-28
CN102811736A (zh) 2012-12-05
MX350206B (es) 2017-08-28
JP2013511995A (ja) 2013-04-11
KR20120115289A (ko) 2012-10-17
NZ600899A (en) 2014-09-26
MX343228B (es) 2016-10-26

Similar Documents

Publication Publication Date Title
SG10201407935YA (en) Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)
WO2013188693A8 (en) Antigen binding constructs to cd3
TN2013000417A1 (en) Antibody polypeptides that antagonize cd40
NZ607969A (en) Cd33 binding agents
CA2849765C (en) Hybrid constant regions
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
IL209277A (en) Antibodies and their antigen-binding segments that bind to the interleukin antibody and interleukin 6 and interleukin 6 receptor complex
IL198379A (en) Human antibodies and antibodies that bind sphingosine-1-phosphate, their encoded nucleic acids, and their preparations and methods for treating the disease
NZ610267A (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
MX357231B (es) Polipeptidos de anticuerpos que antagonizan el ligando cd40 (cd40l).
EA030777B9 (ru) Анти-альфа-синуклеинсвязывающие молекулы
PH12014502527A1 (en) St2 antigen binding proteins
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
MX2013013832A (es) Proteínas de unión receptoras fc.
SG10201804513WA (en) Antibodies Against Fcrn And Use Thereof
MY162791A (en) Anti-il-23 antibodies
CR20120312A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
WO2010081679A3 (en) Antibodies against human epo receptor
MX2010006767A (es) Anticuerpos de virus de hepatitis c.
MX341309B (es) Anticuerpos especificos del heterodimero de anti-il-23.
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
WO2011092593A3 (en) Hiv-1 neutralizing antibodies and uses thereof
MY166152A (en) Anti-human xcr1 antibodies
MX343117B (es) Anticuerpos del receptor eritropoyetina (epo) anti-humana y metodos de uso.
WO2011050104A3 (en) Methods of using anti-cd3 antibodies to prevent weight gain